Breaking: Peer-Reviewed Italian Study Reveals Potential Link Between COVID-19 Vaccination and Elevated Cancer Hospitalization Risk.

A groundbreaking peer-reviewed study published in the EXCLI Journal in July 2025 analyzed official Italian National Health Service data from nearly 300,000 residents (aged 11+) in Pescara province over 30 months (June 2021–December 2023), finding that individuals receiving at least one COVID-19 vaccine dose—primarily mRNA vaccines from Pfizer-BioNTech and Moderna—faced a 23% increased hazard ratio (HR 1.23, 95% CI: 1.11–1.37) for cancer hospitalization compared to the unvaccinated.

This was after adjusting for age, sex, comorbidities, prior cancer, and SARS-CoV-2 infection status. This association held strongest among those without prior COVID-19 infection and within shorter lag times (e.g., 180 days post-vaccination), with elevated risks for breast cancer (HR 1.54), bladder cancer (HR 1.62), and colorectal cancer (HR 1.35), though it reversed after a 12-month lag and showed no increase for lung or prostate cancers. While the study also confirmed a substantial reduction in all-cause mortality among the vaccinated, its authors emphasized preliminary findings due to possible healthy vaccinee bias, unmeasured confounders, and reliance on hospital discharge records as a proxy for new diagnoses rather than confirmed incidence. Epidemiologist Nicholas Hulscher, MPH—not an author on the paper but affiliated with the McCullough Foundation—has highlighted these results in outlets like Science, Public Health Policy and the Law as “first direct evidence” aligning with anecdotal reports of “turbo cancers,” though critics argue the observational design cannot prove causation and aligns with broader vaccine safety data showing no established cancer link.

Source: https://pubmed.ncbi.nlm.nih.gov/40881928/

pubmed.ncbi.nlm.nih.gov

COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province - PubMed

Anecdotal reports suggested an association between SARS-CoV-2 vaccination and some cancers, but no formal assessment has been published. This population-wide cohort analysis was aimed at evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. Using Nation … Continue reading